Alzheimer's Disease & Memory Disorders Center
Rhode Island Hospital

Ongoing Memory Disorders Trials

The following studies are ongoing, but are not currently enrolling new participants.

Clarity AD

This Phase 3 trial will test the effectiveness of the experimental drug BAN2401 as a possible treatment for Alzheimer's disease. BAN2401 is a monoclonal antibody that interferes with the formation of amyloid plaque, a hallmark of Alzheimer's. This 18-month study will test the effectiveness of the study drug in people with MCI or early Alzheimer's disease.

Meet our team